TMCnet News
Pear Therapeutics Announces Publication of New Analysis of Real-World Data Showing Reduction in Insomnia Severity, Healthcare Resource Utilization and Associated Costs in Adults Using Somryst®Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the publication of new results from a health economic analysis of real-world data to evaluate healthcare resource utilization, associated costs and insomnia severity for Somryst® (previously known as SHUTi in its prior incarnation), the only FDA-authorized PDT for the treatment of chronic insomnia. Results showed clinically meaningful reductions in health-related services and costs in the 24-months after Somryst initiation compared to 24-months prior. Further, clinically meaningful reductions in ISI were also found at end-of-treatment at nine weeks compared to baseline. The retrospective analysis was published in the international peer-reviewed journal ClinicoEconomics and Outcomes Research.1 "These real-world data underscore the potential clinical utility and durable economic benefit of a prescription digital therapeutic like Somryst among people with chronic insomnia," said Yuri Maricich, M.D., Chief Medical Officer of Pear Therapeutics. "In the last 24 months, lack of sleep has been exacerbated by the ongoing COVID-19 pandemic and can greatly impact not only day-to-day activities, but also overall quality of life and long-term health. Now, it's especially important to examine digitally delivered treatment options that can address the underlying issues of chronic insomnia." The analysis evaluated real-world data of 248 adult patients with chronic insomnia treated with Somryst over 24-months compared to the 24-months months prior to treatment and found:
Further, by end of treatment at nine weeks compared to baseline at treatment initiation, results found:
The full paper is available online by clicking here. About Somryst® Somryst is the only FDA-authorized therapeutic that delivers guideline recommended first-line treatment for chronic insomnia. Somryst is a 9-week prescription digital therapeutic (PDT) that addresses the underlying issues of chronic insomnia by delivering cognitive behavioral therapy for insomnia (CBTi), an evidence-based approach that trains the brain to sleep. The American Academy of Sleep Medicine and the American College of Physicians clinical guidelines recommend CBTi as first-line treatment for people with chronic insomnia.2,3 Somryst is used on a mobile device, such as a smartphone or tablet and is available by prescription only. A licensed Health Care Provider (HCP) must prescribe Somryst and use of Somryst should be undrtaken only under the supervised care of an HCP. Somryst Indications for Use and Important Safety Information Somryst is a prescription-only digital therapeutic intended to provide a neurobehavioral intervention (Cognitive Behavioral Therapy for Insomnia - CBT-I) to patients 22 years of age and older with chronic insomnia. Somryst treats patients with chronic insomnia by improving a patient's insomnia symptoms. Safety Information and Warnings Somryst is not for everyone. Please use your clinical judgment to determine whether Somryst is right for your patient.
Note: In the early stages of treatment, increased daytime sleepiness may be expected, but it is usually temporary. Please instruct the patient to consult with their Health Care Provider if these experiences do not go away over a few weeks, as it may indicate that they have another sleep disorder or medical condition other than insomnia. Please instruct the patient that if they have trouble staying awake while performing potentially dangerous tasks (like driving) at any point in the treatment, to avoid these dangerous tasks or stop following the sleep restriction component of the therapy. This press release does not include all the information needed to use Somryst safely and effectively. Please see the full Clinician Brief Summary Instructions for Somryst for more information.
About Pear Therapeutics
Forward-Looking Statements
These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Pear and its management are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) delay or reluctance by patients and/or providers to adopt, request or use Pear's products, (ii) the possibility that Pear may be adversely affected by other economic, business, regulatory, and/or competitive factors; (iii) the evolution of the markets in which Pear competes; (iv) the impact of the COVID-19 pandemic on Pear's business; (v) changes in applicable laws or regulations; and (vi) other risks and uncertainties set forth in Pear's filings with the SEC (including those described in the Risk Factors section). These filings will identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and Pear assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. References:
View source version on businesswire.com: https://www.businesswire.com/news/home/20220810005661/en/ |